In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.
EMA’s CHMP recommends approval of BMS’ Opdivo
Opdivo and Yervoy combination is used for the first-line treatment of adult patients with colorectal cancer. Credit: Jo Panuwat D/Shutterstock. The European Medicines Agency’s (EMA)
November 18, 2024